Gastrointestinal segmental remission with oral budesonide therapy for eosinophilic gastrointestinal diseases

J Allergy Clin Immunol Pract. 2024 Oct;12(10):2857-2860.e2. doi: 10.1016/j.jaip.2024.06.028. Epub 2024 Jun 25.

Affiliations

¹ National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Md.
² National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
³ National Cancer Institute, National Institutes of Health, Bethesda, Md.
⁴ National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Md. Electronic address: [email protected].

PMID: 38936661
DOI: 10.1016/j.jaip.2024.06.028

No abstract available

Publication types

Letter
Case Reports

MeSH terms

Administration, Oral
Adult
Budesonide* / administration & dosage
Budesonide* / therapeutic use
Enteritis* / drug therapy
Eosinophilia* / drug therapy
Female
Gastritis* / drug therapy
Humans
Male
Middle Aged
Remission Induction
Treatment Outcome

Substances

Budesonide

Supplementary concepts

Eosinophilic enteropathy